Compare Charles River Laboratories Intl. Inc (CRL) vs Tesla, Inc. (TSLA) Price & Performance

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Tesla (TSLA) trades at $394.76, down 3.18% over 24 hours, with a bearish technical outlook as it tests support near $391. The stock faces valuation concerns with a P/E of 363.47 and P/S of 14.3, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Revenue declined to $94.83B in 2025, and net income margin compressed to 3.95%. Positive developments include regulatory approval for driver-assistance software in Europe (Reuters, 2026-04-10) and strong growth in German registrations (Zacks Investment Research, 2026-04-10).

Tesla's investment case balances high growth potential in autonomy and energy against near-term execution risks and rich valuations. The consensus price target of $409.26 implies modest upside, but competitive pressures and volatile cash flows warrant caution. Investors should focus on execution of the robotaxi and cheaper EV initiatives for catalysts, while monitoring margin recovery and debt levels.